The University of Chicago Header Logo

Mark Kozloff

TitleClinical Associate Professor
InstitutionUniversity of Chicago
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Nathan CO, Hayes DN, Karrison T, Harismendy O, Moore-Medlin T, Vokes EE, Gutkind JS, Neupane P, Mills G, Sargi Z, Seiwert T, Grilley-Olson J, Day T, Gillison M, Wade JL, Feldman L, Jha G, Kozloff M, O'Leary M, Worden FP, Cohen EEW, Flores JM. A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048. PMID: 36194164; PMCID: PMC9722644.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    2. Liang JT, Strickler JH, Cubillo A, Matrana M, Kozloff M, Lowe T, Blaney M, Sahtout M, Naumovski L, Wainberg ZA. Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol. 2022 Sep; 18(27):3011-3020. PMID: 35920133.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    3. Stilgenbauer S, Wendtner CM, Cartron G, Hallek M, Eichhorst B, Kozloff MF, Giever T, Lozanski G, Jiang Y, Huang H, Pignataro DS, Schary W, Humphrey K, Mobasher M, Morschhauser F, Salles G. Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). Haematologica. 2021 11 01; 106(11):2834-2844. PMID: 33121235; PMCID: PMC8561296.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    4. Liauw SL, Ni L, Wu T, Arif F, Cloutier D, Posner MC, Kozloff M, Kindler HL. A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. J Gastrointest Oncol. 2020 Dec; 11(6):1399-1407. PMID: 33457009; PMCID: PMC7807259.
      Citations: 4     
    5. Bendell J, Ciardiello F, Tabernero J, Tebbutt N, Eng C, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal N, Sobrero A, Shi Y, Roberts L, Yan Y, Chang I, Uyei A, Kim T. Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Ann Oncol. 2018 Jun; 29 Suppl 5:v123. PMID: 32177022.
    6. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Chow Maneval E, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol. 2012 Mar; 23(3):688-694. PMID: 32018662.
    7. Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite BN, Kindler HL, Sharma MR. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24. PMID: 31558477; PMCID: PMC6942629.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    8. Eng C, Kim TW, Bendell J, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, IMblaze370 Investigators, Argilés G, Ciardiello F. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861. PMID: 31003911.
      Citations: 214     Fields:    Translation:HumansCTClinical Trials
    9. Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Kozloff M, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J, Melisi D, Simionato F. TGFß receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemother Pharmacol. 2019 05; 83(5):975-991. PMID: 30887178.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    10. Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636. PMID: 30645764.
      Citations: 14     Fields:    Translation:Humans
    11. Melisi D, Macarulla T, Pezet D, Trojan J, Kozloff M, Cleverly A, Smith C, Estrem ST, Gueorguieva I, Lahn MMF, Blunt A, Benhadji KA, Garcia-Carbonero R, Deplanque G, Fuchs M, Oettle H, Tabernero J. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer. 2018 11; 119(10):1208-1214. PMID: 30318515; PMCID: PMC6251034.
      Citations: 113     Fields:    Translation:HumansCellsCTClinical Trials
    12. de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018 09 01; 29(9):1932-1938. PMID: 30060083; PMCID: PMC6158762.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    13. Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395. PMID: 29590007; PMCID: PMC5941614.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    14. Shah S, Wood K, Labadie B, Won B, Brisson R, Karrison T, Hensing T, Kozloff M, Bao R, Patel JD, Luke JJ. Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget. 2018 Jan 12; 9(4):4375-4384. PMID: 29435109; PMCID: PMC5796980.
      Citations: 19     Fields:    
    15. de W Marsh R, Talamonti MS, Baker MS, Posner M, Roggin K, Matthews J, Catenacci D, Kozloff M, Polite B, Britto M, Wang C, Kindler H. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362. PMID: 29044544; PMCID: PMC5890423.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    16. Bendell JC, Hochster H, Hart LL, Firdaus I, Mace JR, McFarlane JJ, Kozloff M, Catenacci D, Hsu JJ, Hack SP, Shames DS, Phan SC, Koeppen H, Cohn AL. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist. 2017 03; 22(3):264-271. PMID: 28209746; PMCID: PMC5344636.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    17. Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP, Kozloff MF. Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016 Dec; 175(5):892-903. PMID: 27861736; PMCID: PMC5132115.
      Citations: 23     Fields:    Translation:Humans
    18. Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92. PMID: 26527777; PMCID: PMC4678179.
      Citations: 239     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    19. Grothey A, Flick ED, Cohn AL, Bekaii-Saab TS, Bendell JC, Kozloff M, Roach N, Mun Y, Fish S, Hurwitz HI. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf. 2014 Jul; 23(7):726-34. PMID: 24830357.
      Citations: 21     Fields:    Translation:Humans
    20. Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, Zafar SY, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Invest New Drugs. 2014 Aug; 32(4):700-9. PMID: 24711126; PMCID: PMC4103954.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    21. Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A, ARIES Study Investigators. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol). 2014 Jun; 26(6):323-32. PMID: 24686090.
      Citations: 17     Fields:    Translation:Humans
    22. Bachelot T, Garcia-Saenz JA, Verma S, Gutierrez M, Pivot X, Kozloff MF, Prady C, Huang X, Khosravan R, Wang Z, Cesari R, Tassell V, Kern KA, Lluch A, Blay JY. Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer. 2014 Mar 07; 14:166. PMID: 24606768; PMCID: PMC3995914.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    23. Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5. PMID: 24386952; PMCID: PMC3893521.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    24. Fuchs CS, Fakih M, Schwartzberg L, Cohn AL, Yee L, Dreisbach L, Kozloff MF, Hei YJ, Galimi F, Pan Y, Haddad V, Hsu CP, Sabin A, Saltz L. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Cancer. 2013 Dec 15; 119(24):4290-8. PMID: 24122767.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    25. Wainberg ZA, Messersmith WA, Peddi PF, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC, Kozloff MF. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2013 Dec; 12(4):248-54. PMID: 24075777.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    26. Pashos CL, Flowers CR, Kay NE, Weiss M, Lamanna N, Farber C, Lerner S, Sharman J, Grinblatt D, Flinn IW, Kozloff M, Swern AS, Street TK, Sullivan KA, Harding G, Khan ZM. Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Support Care Cancer. 2013 Oct; 21(10):2853-60. PMID: 23748484.
      Citations: 16     Fields:    Translation:Humans
    27. Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012; 17(12):1486-95. PMID: 23015662; PMCID: PMC3528380.
      Citations: 41     Fields:    Translation:Humans
    28. Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer. 2012 Oct 09; 107(8):1268-76. PMID: 22996612; PMCID: PMC3494424.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    29. Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB, De Castro Carpeño J. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer. 2012 Oct 09; 107(8):1277-85. PMID: 22990652; PMCID: PMC3494447.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    30. Kabbinavar FF, Flynn PJ, Kozloff M, Ashby MA, Sing A, Barr CE, Grothey A. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012 May; 48(8):1126-32. PMID: 22424880.
      Citations: 20     Fields:    Translation:Humans
    31. de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43. PMID: 22371453; PMCID: PMC4467891.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    32. Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8. PMID: 22100149.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    33. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Chow Maneval E, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol. 2012 Mar; 23(3):688-694. PMID: 21821830; PMCID: PMC4415089.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    34. Polite BN, Sing A, Sargent DJ, Grothey A, Berlin J, Kozloff M, Feng S. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2012 Feb 15; 118(4):1083-90. PMID: 21800287.
      Citations: 20     Fields:    Translation:Humans
    35. Kabbinavar F, Kozloff M. Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'. Oncology. 2011; 80(1-2):135-7; author reply 140-1. PMID: 21677459.
      Citations:    Fields:    Translation:Humans
    36. Catenacci DV, Kozloff M, Kindler HL, Polite B. Personalized colon cancer care in 2010. Semin Oncol. 2011 Apr; 38(2):284-308. PMID: 21421118; PMCID: PMC3065981.
      Citations: 20     Fields:    Translation:HumansCells
    37. Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010; 78(5-6):329-39. PMID: 20733336.
      Citations: 49     Fields:    Translation:Humans
    38. Mayer EL, Dhakil S, Patel T, Sundaram S, Fabian C, Kozloff M, Qamar R, Volterra F, Parmar H, Samant M, Burstein HJ. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Dec; 21(12):2370-2376. PMID: 20497961.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    39. Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol. 2010 Mar; 5(3):354-60. PMID: 20032789.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    40. Kozloff M, Chuang E, Starr A, Gowland PA, Cataruozolo PE, Collier M, Verkh L, Huang X, Kern KA, Miller K. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol. 2010 Jul; 21(7):1436-1441. PMID: 20032126; PMCID: PMC2890319.
      Citations: 14     Fields:    Translation:Humans
    41. Guzman L, Kozloff M, Wallace J, Starr A. Cutaneous eruption related to human epidermal growth factor receptor inhibitors in stage IV colon cancer. Clin J Oncol Nurs. 2009 Oct; 13(5):491-3. PMID: 19793706.
      Citations:    Fields:    Translation:Humans
    42. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, Investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009 Sep; 14(9):862-70. PMID: 19726453.
      Citations: 99     Fields:    Translation:Humans
    43. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23. PMID: 19723643; PMCID: PMC2767337.
      Citations: 96     Fields:    Translation:Humans
    44. Choong NW, Kozloff M, Taber D, Hu HS, Wade J, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83. PMID: 19649772.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    45. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57. PMID: 19201650; PMCID: PMC2768532.
      Citations: 97     Fields:    Translation:HumansCTClinical Trials
    46. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008 Nov 20; 26(33):5326-34. PMID: 18854571.
      Citations: 262     Fields:    Translation:Humans
    47. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11. PMID: 18758303; PMCID: PMC4535721.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    48. Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, Qian J, Hagey AE, Gordon GB. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun; 3(6):631-6. PMID: 18520803.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    49. Faoro L, Cohen EE, Govindan R, Kozloff MF, Hoffman PC, Maitland ML, Verel K, Szeto L, Salgia R, Vokes EE. Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC). J Clin Oncol. 2008 May 20; 26(15_suppl):19130. PMID: 27947490.
    50. Sugrue MM, Purdie DM, Feng S, Flynn PJ, Grothey A, Sargent DJ, Berlin JD, Kabbinavar FF, Dong W, Kozloff MF. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS). J Clin Oncol. 2008 May 20; 26(15_suppl):4105. PMID: 27951076.
    51. Choong NW, Cohen EE, Kozloff MF, Taber D, Wade Iii JL, Hu S, Ivy SP, Nichols K, Dekker A, Vokes EE. Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2008 May 20; 26(15_suppl):6064. PMID: 27950584.
    52. Flynn PJ, Sugrue MM, Feng S, Purdie DM, Grothey A, Sargent DJ, Berlin JD, Kabbinavar FF, Dong W, Kozloff MF. Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS). J Clin Oncol. 2008 May 20; 26(15_suppl):4104. PMID: 27951069.
    53. Kozloff MF, Sugrue MM, Purdie DM, Berlin JD, Flynn PJ, Kabbinavar FF, Sargent DJ, Dong W, Grothey A. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study. J Clin Oncol. 2008 May 20; 26(15_suppl):4026. PMID: 27949319.
    54. Maitland ML, Kasza KE, Lacouture ME, Liu W, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Karrison T, Vokes EE. Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC). J Clin Oncol. 2008 May 20; 26(15_suppl):8089. PMID: 27948963.
    55. Purdie DM, Berlin JD, Flynn PJ, Grothey A, Kabbinavar FF, Kozloff MF, Dong W, Sugrue MM. The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS). J Clin Oncol. 2008 May 20; 26(15_suppl):4103. PMID: 27951066.
    56. Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff MF, Roach N, Sargent DJ, Tezcan H, Grothey A, Purdie DM, Sugrue MM. Initial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line. J Clin Oncol. 2008 May 20; 26(15_suppl):15002. PMID: 27949846.
    57. Eklund J, Kozloff M, Vlamakis J, Starr A, Mariott M, Gallot L, Jovanovic B, Schilder L, Robin E, Pins M, Bergan RC. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. Cancer. 2006 Jun 01; 106(11):2459-65. PMID: 16615097.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    58. Choong NW, Mauer AM, Hoffman PC, Rudin CM, Winegarden JD, Villano JL, Kozloff M, Wade JL, Sciortino DF, Szeto L, Vokes EE. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):245-51. PMID: 17409864.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    59. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40. PMID: 16258101.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    60. Costello S, Wolf MS, Lyons EA, Ray P, Kozloff M, Bennett CL. Variations in treatment of lower SES prostate cancer patients at a VA, a county and a private hospital. J Clin Oncol. 2005 Jun; 23(16_suppl):6072. PMID: 27945926.
    61. Kozloff M, Cohn A, Christiansen N, Flynn P, Kabbinavar F, Robles R, Ulcickas Yood M, Sarkar S, Hambleton J, Grothey A. Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S. J Clin Oncol. 2005 Jun; 23(16_suppl):3566. PMID: 27944443.
    62. Vokes EE, Cohen EE, Mauer AM, Karrison TG, Wong SJ, Skoog-Sluman LJ, Kozloff MF, Dancey J, Dekker A. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol. 2005 Jun; 23(16_suppl):5504. PMID: 27945465.
    63. Boccia R, Bourhis J, Brizel D, Daly C, Holloway N, Hymes S, Koukourakis M, Kozloff M, Turner M, Wasserman T, Anné PR. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys. 2004 Sep 01; 60(1):302-9. PMID: 15337569.
      Citations: 1     Fields:    Translation:Humans
    64. Milano MT, Haraf DJ, Stenson KM, Witt ME, Eng C, Mittal BB, Argiris A, Pelzer H, Kozloff MF, Vokes EE. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32. PMID: 15297392.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    65. Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol. 2004 Mar 15; 22(6):1110-7. PMID: 15020613.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    66. Chen LM, Ignacio L, Jacobs R, Kozloff M, Telfer M, Elahi R, Evans R, Vijayakumar S. Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer. Radiat Oncol Investig. 1999; 7(1):49-53. PMID: 10030624.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    67. Kies MS, Haraf DJ, Athanasiadis I, Kozloff M, Mittal B, Pelzer H, Rademaker AW, Wenig B, Weichselbaum RR, Vokes EE. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998 Aug; 16(8):2715-21. PMID: 9704722.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    68. Walk D, Handelsman A, Beckmann E, Kozloff M, Shapiro C. Mononeuropathy multiplex due to infiltration of lymphoma in hematologic remission. Muscle Nerve. 1998 Jun; 21(6):823-6. PMID: 9585343.
      Citations: 3     Fields:    Translation:Humans
    69. Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain MJ. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71. PMID: 8622086.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    70. Blend MJ, Hyun H, Kozloff M, Levi H, Mills GQ, Gasparini M, Buraggi G, Hughes L, Pinsky CM, Goldenberg DM. Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment. Cancer Res. 1995 Dec 01; 55(23 Suppl):5764s-5770s. PMID: 7493343.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    71. Vokes EE, Kies M, Haraf DJ, Mick R, Moran WJ, Kozloff M, Mittal B, Pelzer H, Wenig B, Panje W, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol. 1995 Apr; 13(4):876-83. PMID: 7707114.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    72. Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, Hamasaki V, Weichselbaum RR, Panje WR, Wenig B, et al. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8. PMID: 8426214.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    73. Ramadurai J, Shapiro C, Kozloff M, Telfer M. Zinc abuse and sideroblastic anemia. Am J Hematol. 1993 Feb; 42(2):227-8. PMID: 8438885.
      Citations: 1     Fields:    Translation:Humans
    74. Vokes EE, Haraf DJ, McEvilly JM, Mick R, Kozloff MF, Goldman MD, Moran WJ, Clendeninn NJ, Collier MA, Weichselbaum RR, et al. Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol. 1992 Jan; 3(1):79-81. PMID: 1606074.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    75. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol. 1991 Nov; 18(11):1741-3. PMID: 1787499.
      Citations: 62     Fields:    Translation:Humans
    76. Vokes EE, Panje WR, Mick R, Kozloff MF, Moran WJ, Sutton HG, Goldman MD, Tybor AG, Weichselbaum RR. A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer. 1990 Jul 15; 66(2):206-13. PMID: 2196107.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    77. Vokes EE, Schilsky RL, Weichselbaum RR, Kozloff MF, Panje WR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7. PMID: 1688926.
      Citations: 12     Fields:    Translation:Humans
    78. Bitran JD, Kozloff MF, Desser RK. Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II study. Cancer Invest. 1990; 8(3-4):335-8. PMID: 2207758.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    79. Bitran JD, Desser RK, Shapiro CM, Michel A, Kozloff MF, Billings AA, Recent W. Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. Cancer. 1983 Feb 01; 51(3):381-4. PMID: 6821824.
      Citations: 4     Fields:    Translation:Humans
    80. Bitran JD, Desser RK, Schifeling D, Shapiro CM, Kozloff MF, Robin E, Recant W, Michel A, Rochman H, Billings AA. Multimodality therapy of stage III adenocarcinoma of the breast. J Surg Oncol. 1983 Jan; 22(1):5-8. PMID: 6687399.
      Citations: 1     Fields:    Translation:Humans
    81. Bitran JD, Desser RK, Billings AA, Kozloff MF, Shapiro CM. Acute nephrotoxicity following cis-dichlorodiammine-platinum. Cancer. 1982 May 01; 49(9):1784-8. PMID: 7200396.
      Citations: 19     Fields:    Translation:Humans
    82. Shapiro CM, Schifeling D, Bitran JD, Desser RK, Rochman H, Michel A, Shapiro R, Evans R, Kozloff MF, Recant W, Billings AA. Prognostic value of the estrogen receptor level in pathologic stage I and II adenocarcinoma of the breast. J Surg Oncol. 1982 Feb; 19(2):119-21. PMID: 7057648.
      Citations: 8     Fields:    Translation:Humans
    83. Ashenhurst J, Bitran JD, Robin E, Desser RK, Shapiro C, Kozloff MF, Billings AA. Melphalan, vincristine, and 5-FU in advanced colonic carcinoma: results of a pilot study. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):869-72. PMID: 7273020.
      Citations:    Fields:    Translation:Humans
    84. Bitran JD, Brown C, Desser RK, Kozloff MF, Shapiro C, Billings AA. Intracavitary bleomycin for the control of malignant effusions. J Surg Oncol. 1981; 16(3):273-7. PMID: 6163930.
      Citations: 8     Fields:    Translation:Humans
    85. Bitran JD, Desser RK, Kozloff MF, Billings AA, Shapiro CM. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM). Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2049-51. PMID: 393388.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    Kozloff's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (291)
    Co-Authors (35)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors